SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XFloki is a meme-inspired cryptocurrency project launched on the Ethereum network, themed around Elon Musk’s pet dog, who is humorously referred to as the “CEO of X.” The project aims to merge meme culture, blockchain technology, and community engagement through a decentralized platform that highlights entertainment, creativity, and innovation in Web3. XFloki distinguishes itself by combining Ethereum-based smart contracts with a strong narrative centered on Elon Musk’s symbolic leadership of X through his dog, Floki. It integrates interactive website features, governance participation, and token utility, offering the community a structured yet entertaining ecosystem rooted in transparency and decentralization.

NEW X CEO IS BACK

XFLOKI is experiencing intense social media attention as investors debate its legitimacy, with many participants warning of potential liquidity issues and labeling the asset a high-risk scam despite rapid, unsubstantiated valuation gains.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is generating significant discussion as investors weigh the project's institutional privacy ambitions against concerns regarding its decentralized rollout and heavy Google Cloud involvement. While some in the community see the integration with traditional banking and robust ZK-proof technology as a long-term catalyst, others remain skeptical, frequently drawing comparisons to broader Cardano ecosystem volatility and past airdrop distribution challenges.

SLEEPLESS COIN

Sleepless Coin is gaining significant social momentum following rumors of a potential buyout and a rapid price surge, though community members remain divided over the project's long-term sustainability versus its speculative growth. Investors are actively debating the token's link to the Solana ecosystem while weighing the risks of high volatility against the current wave of market excitement.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors monitor ongoing project development and anticipate a major tenant announcement, with sentiment heavily influenced by the firm's strategic positioning in the high-demand AI infrastructure and data center energy sector. The community is actively debating the significance of recent financing milestones, management's ability to secure large-scale contracts, and potential volatility stemming from lock-up expirations and legal headwinds.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently trending due to a combination of strong earnings performance, strategic menu value initiatives like the anticipated value menu expansion, and ongoing community debate regarding executive compensation and food quality. Investors are closely watching its resilience as a defensive play, while social media chatter focuses on menu innovation, the impact of value-driven promotions on traffic, and the broader debate over CEO alignment with company products.

Dogelon Mars

Dogelon Mars continues to trend on social platforms as the community maintains its strong, long-term commitment, often discussing the potential for a future breakthrough despite recent volatility. Supporters frequently compare the token's persistent branding and market cap to other major meme coins, viewing it as an overlooked project with high speculative potential.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing extreme volatility as retail investors scramble to gain exposure to high-profile private tech companies like Anthropic and SpaceX, leading to intense debates over whether the fund's massive valuation premium is justified or an unsustainable bubble. Community sentiment is deeply polarized, with many investors holding shares for long-term venture access while others warn of a looming crash as short-sellers face significant difficulty finding borrowable shares.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is experiencing heightened volatility and social debate as investors weigh speculative partnerships and integration news against broader bearish market sentiment and persistent concerns regarding price action. The community remains deeply polarized, with some accumulating positions in anticipation of a potential bull run while others criticize the asset's long-term performance and market relevance.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is trending as investors digest a strong earnings beat and positive long-term guidance, leading the stock to show notable relative strength against a volatile tech sector. The community is actively debating the company's aggressive pivot toward in-house AGI CPU production for data centers, with many traders focused on whether this shift validates its premium valuation or introduces new execution risks.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the subject of intense speculation as investors weigh reports of a potential strategic merger with SpaceX by 2027 alongside ongoing global volatility. The community remains deeply polarized, with some bulls highlighting long-term infrastructure synergies and potential market rebounds, while bearish voices cite declining margins, aggressive insider selling, and significant macro-economic pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks

Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.

VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing, competitive weight-loss market.

<ul class="summary-bullets"><li>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735.&nbsp;</li><li>Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.</li><li>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.</li></ul>Shares of Viking Therapeutics Inc. (VKTX) closed 3% higher on Thursday amid speculation for a buyout, and an eventual approval from the U.S. Food and Drug Administration for its experimental obesity drug dubbed the “Ozempic killer.”A Stocktwits user recommended holding the stock, opining that it would remain “slow and steady” until FDA approval.<stembedurl>https://stocktwits.com/GREENCANDLELOVER/message/648672982</stembedurl>Another speculated a “big buyout" for the company.<stembedurl>https://www.stocktwits.com/timfris/message/648671668</stembedurl>Another user highlighted that the company’s obesity asset can dethrone Eli Lilly and Co.’s (LLY) supremacy in the obesity drug segment.<stembedurl>https://www.stocktwits.com/TrustButVerifi/message/648663298</stembedurl>Yet another user called the company’s obesity drug the “Ozempic killer.”<stembedurl>https://www.stocktwits.com/MetricWhale/message/648678023</stembedurl>Overall, retail sentiment around the stock improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.<h2 class="st-heading-2">Viking Completes Trial Enrollment</h2>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. The trial enrolled about 1,000 patients with type 2 diabetes and who have obesity or who are overweight, the company said. The primary endpoint of the study is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The dual agonist VK2735 is being developed in both oral and subcutaneous formulations. Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.<h2 class="st-heading-2">Company Stays Bullish On Pipeline</h2>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.“2025 was a big year for us. 2026 is gonna be a big year as well,” Lian said at the Leerink Global Healthcare Conference.The CEO also expressed optimism that weight loss for the subcutaneous VK2735 trials will probably be a “little better than a GLP-1 monoagonist” though he couldn't predict its impact in comparison to other "polyagonists." While Novo Nordisk’s popular weight loss drug Wegovy is a single-agonist drug, Eli Lilly and Company’s Zepbound is a dual agonist.Viking is also looking to file an application to start trials for a novel amylin agonist this quarter, as it seeks to expand its obesity portfolio. Amylin agonists are a class of medication that mimic the hormone amylin, which is co-secreted with insulin by pancreatic -cells to manage glucose levels and appetite.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained more than 30% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-teases-three-row-tesla-suv-but-fails-to-ease-delivery-growth-fears/cZ3sEBvRIlE">Elon Musk Teases Three-Row Tesla SUV But Fails To Ease Delivery Growth Fears</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 

Equity

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 


Viking Therapeutics (NASDAQ:VKTX) Now Covered by Wolfe Research

Wolfe Research assumed coverage on shares of Viking Therapeutics in a report on Thursday. They set a "peer perform" rating for the company...

<ul class="summary-bullets"><li>Viking is developing VK2735 in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.</li><li>The company stated that the primary endpoint of the Phase 3 VANQUISH-2 study is the percentage change in body weight from baseline for participants receiving VK2735.</li><li>The company stated it expects to complete the VANQUISH studies in 2027.</li></ul>Viking Therapeutics Inc. (VKTX) on Thursday announced that it has completed enrollment in the Phase 3 trial of its obesity drug, VK2735, which is in the race to compete in the GLP-1 obesity drug market, dominated by Novo Nordisk's Ozempic and Wegovy.The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.Viking is developing VK2735 in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics shares</a> were up nearly 2% in Thursday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory.<h2 class="st-heading-2">What Are The Primary And Secondary Endpoints?</h2>Viking Therapeutics stated that the primary endpoint of the Phase 3 VANQUISH-2 study is the percentage change in body weight from baseline for participants receiving VK2735, compared to patients on placebo after 78 weeks of treatment.The secondary and exploratory endpoints include an evaluation of several efficacy and safety measures. This includes the percentage of patients who achieve 5%, 10%, 15% and 20% or more body weight reduction during the trial.“As with the VANQUISH-1 study, we are happy to see a study of this size enroll quickly, which we believe speaks to the enthusiasm for new obesity treatments beyond those currently available,” said Viking CEO Brian Lian.The company stated it expects to complete the VANQUISH studies in 2027.<h2 class="st-heading-2">Phase 3 Trial Update</h2>Viking also announced an update regarding its Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients who have obesity or are overweight.The company also stated that it is evaluating VK2735 in a Phase 1 study evaluating a range of potential maintenance dosing regimens. Results from the maintenance study are expected in the third quarter (Q3) of 2026.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 6% year-to-date, but up 19% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 42% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF (VBK) is up 18%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-iran-begging-for-deal-warns-get-serious-on-talks-dow-futures-fall/cZ3ru8hRIjM">Trump Says Iran ‘Begging’ For Deal, Warns Them To 'Get Serious’ On Talks — Dow Futures Fall More Than 300 Points</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress

The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 PR Newswire...

Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.17, denoting a -1.17% move from the preceding trading day.

Why Viking Therapeutics Stock Could Take Off Later This Year

Key PointsViking's GLP-1 drug, VK2735, is currently in the midst of multiple clinical trials...

HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX)

HC Wainwright restated a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a report on Monday...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VKTX News

VKTXViking Therapeutics Inc